News

"We are very excited having selected PPD, one of the world’s leading contract research organizations, to be our strategic clinical development partner in advancing our assets through the

The audit will be conducted in two phases, both of which are expected to be completed by early November 2014. In the first phase, INC Research Quality and

Triumeq is a once-daily single-pill regimen, which combines the integrase strand transfer inhibitor (INSTI) dolutegravir with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine. ViiV Healthcare Canada

Opdivo (nivolumab) is BMS’s investigational PD-1 immune checkpoint inhibitor, while Imbruvica (ibrutinib) is an oral Bruton’s tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The

Orexo anticipates a potential approval of the expanded label during the third quarter 2015. The application for initiation of treatment is supported by the data from the ISTART

Hodgkin lymphoma is a cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types

"We are elated following the FDA’s approval of our IND application for MT-3724 and are eager to begin the next steps of our clinical journey with Veristat. Veristat

CVC blocks two chemokine receptors, CCR2 and CCR5, which are intricately involved in the inflammatory and fibrogenic pathways in NASH that cause liver damage and often lead to

If granted, the FDA orphan drug designation will provide the company special development and commercial assistance, including a seven year period of marketing exclusivity. In September, the company